Showing results (181-190 of 192) with videos related to

Sort By:
Pageof 20
Frontiers in Toxicology|May 2, 2024
The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours developScott A Fisher, Kimberley Patrick, Tracy Hoang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 1, 2020
Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural MesotheliomaFerdinando Cerciello, Meena Choi, Sara L Sinicropi-Yao, et al.
Oncoimmunology|February 1, 2020
Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesotheliomaSophie Sneddon, Craig M Rive, Shaokang Ma, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2021
Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is usedVanessa S Fear, Catherine A Forbes, Samuel A Neeve, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 4, 2018
Scientific Advances and New Frontiers in Mesothelioma TherapeuticsLuciano Mutti, Tobias Peikert, Bruce W S Robinson, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 9, 2020
Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non-Small Cell Lung CancerQingzhu Jia, Luting Chiu, Shuangxiu Wu, et al.
Thorax|July 20, 2014
Comparison of fibulin-3 and mesothelin as markers in malignant mesotheliomaJenette Creaney, Ian M Dick, Tarek M Meniawy, et al.
Gene|March 23, 2015
Absence of germline mutations in BAP1 in sporadic cases of malignant mesotheliomaSophie Sneddon, Justine S Leon, Ian M Dick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2015
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesotheliomaA K Nowak, A M Cook, A M McDonnell, et al.
Plos One|September 12, 2009
Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growthRobbert G van der Most, Andrew J Currie, Amanda L Cleaver, et al.
Pageof 20